Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis

Journal of Medical Economics

Volumn 16, Issue 4, 2013, Pages 479-489

  Kirson, Noam Y ^a   Rao, Sumati ^b   Birnbaum, Howard G ^a   Kantor, Evan ^a   Wei, Robert S ^a   Cifaldi, Mary ^b  

^a ANALYSIS GROUP   (United States)

^b ABBVIE INC   (United States)

Author keywords

Clinical trials; Costs and cost analysis; Indirect comparison; Psoriatic arthritis; Treatment efficacy; Tumor necrosis factor alpha

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; DRUG COST; FEMALE; GENDER; GERMANY; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PSORIATIC ARTHRITIS; SHORT FORM 36; UNITED STATES;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; DRUG THERAPY, COMBINATION; FEMALE; HEALTH EXPENDITURES; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PATIENT ACUITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, TUMOR NECROSIS FACTOR; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84875727763     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.768530     Document Type: Article

References (32)

1. Gladman DD. Psoriatic arthritis. Dermatol Ther 2009;22:40-55
2. Gladman DD, Stafford-Brady F, Chang CH, et al. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J. Rheumatol 1990;17:809-12
3. Queiro-Silva R, Torre-Alonso JC, Tinture-Eguren T, et al. A polyarticular onset predicts erosive and deforming disease in psoriatic arthritis. Ann Rheum Dis 2003;62:68-70
4. Husted J, Gladman DD, Long JA, et al. Validating the SF-36 health questionnaire in patients with psoriatic arthritis. J Rheumatol 1997;24:511-7
5. Husted JA, Gladman DD, Farewell VT, et al. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Care Res 2001;45:151-8
6. Sokoll KB, Helliwell PS. Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol 2001;28:1842-6
7. Husted JA, Tom BD, Farewell VT, et al. A longitudinal study of the effect of disease activity and clinical damage on physical function over the course of psoriatic arthritis: does the effect change over time? Arthritis Rheum 2007;56:840-9
8. Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 2005;53:573-7
9. Van Voorhees A, Feldman SR, Koo JYM, et al. The psoriasis and psoriatic arthritis pocket guide: treatment algorithms and management options. Portland: National Psoriasis Association, 2009. http://www.psoriasis.org/Document.Doc?id= 354. Accessed May 6, 2010
10. Shbeeb M, Uramoto KM, Gibson LE, et al. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol 2000;27:1247-50
11. Leonard DG, O'Duffy JD, Rogers RS. Prospective analysis of psoriatic arthritis in patients hospitalized for psoriasis. Mayo Clin Proc 1978;53:511-8
12. Boumpas DT, Illei GG, Tassiulas IO. Psoriatic arthritis. In: Klippel JH, editor. Primer on the rheumatic diseases. 12th ed. Atlanta, GA: The Arthritis Foundation, 2001. p 233-7
13. Ceponis A, Kavanaugh A. Treatment of psoriatic arthritis with biological agents. Semin Cutan Med Surg 2010;29:56-62
14. Saber TP, Veale DJ. Psoriatic arthritis management update-biotherapeutic options. J Rheumatol Suppl 2009;83:65-8
15. Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91
16. Saad AA, Symmons DP, Noyce PR, et al. Risk and benefits of tumour necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and meta-analysis of randomized controlled trials. J Rheumatol 2008;35:883-90
17. Migliore A, Bizzi E, Broccoli S, et al. Indirect comparison of etanercept, infliximab, and adalimumab for psoriatic arthritis: mixed treatment comparison using placebo as common comparator. Clin Rheumatol 2012 Jan; 31:193-4. doi: 10.1007/s10067-011-1862-7 [Epub 2011 Oct 18].
18. Glenny AM, Altman DG, Song F, et al. Indirect comparisons of competing interventions. Health Technol Assess 2005;9:1-134
19. Sutton A, Ades AE, Cooper N, et al. Use of indirect and mixed treatment comparisons for technology assessment. Pharmacoeconomics 2008;26:753-67
20. Phillips A. 2003 Trial and Error: cross-trial comparisons of antiretroviral regimens. AIDS 2003;17:6-23
21. Cranney A, Guyatt G, Griffith L, et al. Meta-analyses of therapies for postmenopausal osteoporosis. IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002;23:570-8
22. Deeks JJ, Higgins, JPT, Altman DG. Analysing and presenting results. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]; Section 8. The Cochrane Library. Chichester, UK: John Wiley & Sons, Ltd, 2006
23. Signorovitch JE, Wu EQ, Yu AP, et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. PharmacoEconomics 2010;28:935-45
24. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis. Arthritis Rheum 2005;52:279-89
25. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264-72
26. Antoni C, Kruger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64:1150-7
27. Rodgers M, Epstein D, Bojke L, et al. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess. 2011 Feb;15:i-xxi, 1-329. doi: 10.3310/hta15100. Review.
28. Genovese MC, Mease PJ, Thomson GT, et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol 2007;34:1040-50
29. Casella G, Berger RL. Statistical inference. Pacific Grove, CA: Duxbury, Thomson Learning, 2002
30. Red Book Drug Topics. Montvale, NJ: Thomson Healthcare, 2010
31. Lauer-Taxe online. Online Pharmaceutical Database 2010. Fürth: Lauer-Fischer GmbH, 2010
32. Signorovitch J, Erder MH, Xie J, et al. Comparative effectiveness research using matching-adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attentiondeficit/hyperactivity disorder and comorbid oppositional defiant disorder. Pharmacoepidemiol Drug Saf 2012;21(2 Suppl):130-7